mhurhangee/patent-ind-claim-en huggingface dataset:
A contact-less priming system for loading a solution in a microfluidic device comprising: - at least one microfluidic device comprising at least one first port , at least one second port and at least one microchannel , wherein each of said at least one first and second ports are fluidly connected to said at least one microchannel and wherein said at least one first port is suitable for containing at least one solution; - a pressure chamber with at least one closable, gas tight aperture, configured to enclose said at least one microfluidic device; - a pressurization unit fluidly connected to the pressure chamber for applying pressure in the pressure chamber and upon the at least one first port and at least one second port ; and - at least one closing member configured to close at least partially and/or to open at least partially a port, wherein said at least one closing member is disposed on the at least one first port or the at least one second port . - at least one microfluidic device comprising at least one first port , at least one second port and at least one microchannel , wherein each of said at least one first and second ports are fluidly connected to said at least one microchannel and wherein said at least one first port is suitable for containing at least one solution; - a pressure chamber with at least one closable, gas tight aperture, configured to enclose said at least one microfluidic device; - a pressurization unit fluidly connected to the pressure chamber for applying pressure in the pressure chamber and upon the at least one first port and at least one second port ; and - at least one closing member configured to close at least partially and/or to open at least partially a port, wherein said at least one closing member is disposed on the at least one first port or the at least one second port .
A combination comprising: a retinoid selected from retinol, retinaldehyde, and retinoic acid in its various stereoisomeric forms, and a compound of the following general formula (I): wherein: ▪ n is an integer between 0 and 15, ▪ m is 0, 1, 2 or 3, and ▪ R is the hydrocarbon chain of a polyunsaturated fatty acid selected from omega-3s and omega-6s, wherein: a polyunsaturated fatty acid is a linear carboxylic acid comprising 10 to 28 carbon atoms, including the carbon atom of the carboxylic acid function, and comprising at least 2 C=C double bonds, an omega-3 is a polyunsaturated fatty acid in which the first double bond of the chain corresponds to the third carbon-carbon bond counting from the end opposite the carboxylic acid function, and an omega-6 is a polyunsaturated fatty acid in which the first double bond of the chain corresponds to the sixth carbon-carbon bond counting from the end opposite the carboxylic acid function. a retinoid selected from retinol, retinaldehyde, and retinoic acid in its various stereoisomeric forms, and a compound of the following general formula (I): wherein: ▪ n is an integer between 0 and 15, ▪ m is 0, 1, 2 or 3, and ▪ R is the hydrocarbon chain of a polyunsaturated fatty acid selected from omega-3s and omega-6s, wherein: a polyunsaturated fatty acid is a linear carboxylic acid comprising 10 to 28 carbon atoms, including the carbon atom of the carboxylic acid function, and comprising at least 2 C=C double bonds, an omega-3 is a polyunsaturated fatty acid in which the first double bond of the chain corresponds to the third carbon-carbon bond counting from the end opposite the carboxylic acid function, and an omega-6 is a polyunsaturated fatty acid in which the first double bond of the chain corresponds to the sixth carbon-carbon bond counting from the end opposite the carboxylic acid function. ▪ n is an integer between 0 and 15, ▪ m is 0, 1, 2 or 3, and ▪ R is the hydrocarbon chain of a polyunsaturated fatty acid selected from omega-3s and omega-6s, a polyunsaturated fatty acid is a linear carboxylic acid comprising 10 to 28 carbon atoms, including the carbon atom of the carboxylic acid function, and comprising at least 2 C=C double bonds, an omega-3 is a polyunsaturated fatty acid in which the first double bond of the chain corresponds to the third carbon-carbon bond counting from the end opposite the carboxylic acid function, and an omega-6 is a polyunsaturated fatty acid in which the first double bond of the chain corresponds to the sixth carbon-carbon bond counting from the end opposite the carboxylic acid function.
A computer-assisted medical device comprising: a first articulated arm with an imaging device mounted thereto; a second articulated arm with an instrument having an end effector mounted thereto; a control unit coupled to the first articulated arm and second articulated arm , wherein the control unit is configured to: set a first reference frame, the first reference frame being based on a position of the imaging device at a first time, characterized in that the control unit is further configured to: allow a first disturbance to the first articulated arm , the first disturbance moving the imaging device away from the position of the imaging device at the first time, receive a command to move the end effector after the first time, and transform the command to move the end effector from the first reference frame to a command to move the end effector in a reference frame for the end effector . a first articulated arm with an imaging device mounted thereto; a second articulated arm with an instrument having an end effector mounted thereto; a control unit coupled to the first articulated arm and second articulated arm , wherein the control unit is configured to: set a first reference frame, the first reference frame being based on a position of the imaging device at a first time, characterized in that the control unit is further configured to: allow a first disturbance to the first articulated arm , the first disturbance moving the imaging device away from the position of the imaging device at the first time, receive a command to move the end effector after the first time, and transform the command to move the end effector from the first reference frame to a command to move the end effector in a reference frame for the end effector . set a first reference frame, the first reference frame being based on a position of the imaging device at a first time, characterized in that the control unit is further configured to: allow a first disturbance to the first articulated arm , the first disturbance moving the imaging device away from the position of the imaging device at the first time, receive a command to move the end effector after the first time, and transform the command to move the end effector from the first reference frame to a command to move the end effector in a reference frame for the end effector . allow a first disturbance to the first articulated arm , the first disturbance moving the imaging device away from the position of the imaging device at the first time, receive a command to move the end effector after the first time, and transform the command to move the end effector from the first reference frame to a command to move the end effector in a reference frame for the end effector .
A refrigerator comprising: a main body including a storage chamber ; a door to open or close the storage chamber, the door having a door panel (P) to form an inside surface of the door facing the storage chamber when the door is closed and side surface chassis (S3) to form an opposite side surfaces of the door , the door panel (P) including a gasket mounting portion (P1) at an edge portion of the door panel (P), the gasket mounting portion (P1) having a groove recessed from the inside surface of the door panel (P); a gasket mounted to the gasket mounting portion (P1) to seal the storage chamber when the door is closed and fixed by the door panel (P); and air exhaust holes (H) formed at the groove and covered by the gasket , the air exhaust holes (H) being configured for discharging air from within the door . a main body including a storage chamber ; a door to open or close the storage chamber, the door having a door panel (P) to form an inside surface of the door facing the storage chamber when the door is closed and side surface chassis (S3) to form an opposite side surfaces of the door , the door panel (P) including a gasket mounting portion (P1) at an edge portion of the door panel (P), the gasket mounting portion (P1) having a groove recessed from the inside surface of the door panel (P); a gasket mounted to the gasket mounting portion (P1) to seal the storage chamber when the door is closed and fixed by the door panel (P); and air exhaust holes (H) formed at the groove and covered by the gasket , the air exhaust holes (H) being configured for discharging air from within the door .
A molding system for fabricating a part, the molding system comprising: a first mold section defining a first mold cavity ; a first insert slidable to a plurality of positions relative to the first mold cavity to adjust a dimension of the mold cavity ; a second mold section to be disposed adjacent to the first mold section to at least partially enclose the first mold cavity ; a molding material conduit to be disposed in fluid communication with the first mold cavity ; and a positioning mechanism configured to move the first insert to the plurality of positions relative the first mold cavity ; characterized in that the mechanism comprises a wedge having an angled surface , wherein the mechanism bears on a corresponding angled surface of the first insert to allow the insert to be positioned at essentially any position along the continuum from a front end of the mold cavity to a practical rear boundary, and the molding system further comprises a sliding locking mechanism coupling the wedge to the first insert ; and wherein the molding system further comprises a second mechanism configured to position the solidified molding material in the mold cavity . a first mold section defining a first mold cavity ; a first insert slidable to a plurality of positions relative to the first mold cavity to adjust a dimension of the mold cavity ; a second mold section to be disposed adjacent to the first mold section to at least partially enclose the first mold cavity ; a molding material conduit to be disposed in fluid communication with the first mold cavity ; and a positioning mechanism configured to move the first insert to the plurality of positions relative the first mold cavity ; characterized in that the mechanism comprises a wedge having an angled surface , wherein the mechanism bears on a corresponding angled surface of the first insert to allow the insert to be positioned at essentially any position along the continuum from a front end of the mold cavity to a practical rear boundary, and the molding system further comprises a sliding locking mechanism coupling the wedge to the first insert ; and wherein the molding system further comprises a second mechanism configured to position the solidified molding material in the mold cavity .
A device for assessing hyperinflation in a monitored subject, the device comprising: - respiration monitoring means for collecting respiratory data of the subject at different levels of exertion, the respiratory data at least relating to instantaneous lung volume and comprising the end expiratory lung volume (EELV) after expirations; - exertion level monitoring means for collecting exertion level data of the subject at the different levels of exertion, the exertion level data at least relating to instantaneous oxygen demand and comprising heart rate, as measured by a heart rate measuring device, or breathing frequency , obtained from the respiratory data; - computing means for - establishing a parametric relation between the collected respiratory data and the collected exertion level data, the parametric relation being described by one or more parameters; and - assessing the presence of hyperinflation in the subject in terms of the value of the one or more parameters. - respiration monitoring means for collecting respiratory data of the subject at different levels of exertion, the respiratory data at least relating to instantaneous lung volume and comprising the end expiratory lung volume (EELV) after expirations; - exertion level monitoring means for collecting exertion level data of the subject at the different levels of exertion, the exertion level data at least relating to instantaneous oxygen demand and comprising heart rate, as measured by a heart rate measuring device, or breathing frequency , obtained from the respiratory data; - computing means for - establishing a parametric relation between the collected respiratory data and the collected exertion level data, the parametric relation being described by one or more parameters; and - assessing the presence of hyperinflation in the subject in terms of the value of the one or more parameters. - establishing a parametric relation between the collected respiratory data and the collected exertion level data, the parametric relation being described by one or more parameters; and - assessing the presence of hyperinflation in the subject in terms of the value of the one or more parameters.
A cryocooler, comprising a shell , a compression unit , an expansion unit and a vibration damping unit , wherein a cavity is provided in the shell , the compression unit and the vibration damping unit are located in the cavity , the compression unit is connected to the shell , and the expansion unit is partially located in the cavity and communicates with the compression unit ; the vibration damping unit is sleeved on the compression unit , is partially located in the compression unit and is configured to reduce vibration of the compression unit .
A peptide consisting of the amino acid sequence LSSTQAQQSY (SEQ ID NO: 1).
A transcatheter, implantable, prosthetic heart valve, comprising: a frame ; and two or more integrated cusp and leaflet folded structures attached to the frame , the two or more integrated cusp and leaflet folded structures each comprising a flat sheet of biocompatible membrane that has been folded to include a mobile leaflet section and a cusp wall section , wherein two non-transverse diagonally oriented folds are located between the mobile leaflet section and the cusp wall section , wherein the cusp wall section is located radially outside of the mobile leaflet section , and wherein the cusp wall section includes a seam that joins apposing sides of the cusp wall section . a frame ; and two or more integrated cusp and leaflet folded structures attached to the frame , the two or more integrated cusp and leaflet folded structures each comprising a flat sheet of biocompatible membrane that has been folded to include a mobile leaflet section and a cusp wall section , wherein two non-transverse diagonally oriented folds are located between the mobile leaflet section and the cusp wall section , wherein the cusp wall section is located radially outside of the mobile leaflet section , and wherein the cusp wall section includes a seam that joins apposing sides of the cusp wall section .
Combination of a sealing profile and a backlit trim strip arranged on the sealing profile for a motor vehicle, the trim strip having a profiled strip which, when finally mounted on the motor vehicle as intended, defines a decorative side (Z) directed away from the motor vehicle and having an outwardly visible decorative surface , and a functional side (F) directed towards the vehicle, the decorative surface being bounded by a lower visible edge , and the combination of sealing profile and trim strip being designed in such a way that, when finally mounted on the motor vehicle as intended, a light gap bounded by the lower visible edge and extending along the profiled strip remains, from which the light emitted by the lighting means can visibly emerge to the outside, wherein an optical waveguide arranged on the side of the functional side (F) is provided as lighting means, which is capable of backlighting at least a part of the profiled strip , and the sealing profile or the trim strip forms a holder for the optical waveguide , which is designed in such a way that the optical waveguide inserted into the holder is able to illuminate the light gap .
A hearing device , comprising a first housing for being worn at and/or in a first ear of a user, and a processing unit configured to control functionality of the hearing device , characterized in that, the hearing device further comprises a first radar sensor configured for obtaining first radar data indicative of a shape of a first pinna of the first ear, wherein the first radar sensor is arranged on or near an outer surface of the first housing of the hearing device , wherein arranged near the outer surface is understood as within 0-10 mm of the outer surface, and wherein the processing unit is further configured to: • receive the first radar data from the first radar sensor , • determine, based on the received first radar data, a shape of the first pinna, and • outputting the shape of the first pinna. • receive the first radar data from the first radar sensor , • determine, based on the received first radar data, a shape of the first pinna, and • outputting the shape of the first pinna.
A method for determining aggregate flow of blood through vasculature in a tissue area of interest, comprising, using a near-infrared fluorescence imaging system: measuring a cross-sectional area of a tissue volume end; obtaining a sequence of angiographic images of the tissue volume; calculating average fluorescence intensities for the sequence of angiographic images of the tissue volume; generating a plot of time-varying average fluorescence intensity; from the plot determining a thickness increase of a blood volume layer; a pulse duty cycle; and a duration of a single blood pressure pulse; and deriving the aggregate blood flow, F, according to the inequality F = ΔV P DC / Δ ⁢ t , wherein ΔV = (cross-sectional area of the tissue volume end, A) × (thickness increase, ΔL, of the blood volume layer, L), P DC is the pulse duty cycle and Δt = duration of a single pressure pulse. measuring a cross-sectional area of a tissue volume end; obtaining a sequence of angiographic images of the tissue volume; calculating average fluorescence intensities for the sequence of angiographic images of the tissue volume; generating a plot of time-varying average fluorescence intensity; from the plot determining a thickness increase of a blood volume layer; a pulse duty cycle; and a duration of a single blood pressure pulse; and a thickness increase of a blood volume layer; a pulse duty cycle; and a duration of a single blood pressure pulse; and deriving the aggregate blood flow, F, according to the inequality F = ΔV P DC / Δ ⁢ t , wherein ΔV = (cross-sectional area of the tissue volume end, A) × (thickness increase, ΔL, of the blood volume layer, L), P DC is the pulse duty cycle and Δt = duration of a single pressure pulse.
A compound according to Formula (I): wherein: Q is phenylene or pyridylene, each of which is optionally substituted with one or two substituents selected from halogen, methyl, -CH 2 F, -CHF 2 , or -CF 3 ; Z is: L is selected from the group consisting of a bond, C 1-3 -alkylene, and C 1-3 -alkylene-O-; Y' is phenyl or pyridyl, wherein said phenyl and pyridyl are substituted with one, two, or three groups selected from halogen, C 1-3 -alkyl, fluoro-C 1-3 -alkyl, C 1-3 -alkoxy, and fluoro-C 1-3 -alkoxy; R 1 is C 1-4 -alkyl or C 3-6 -cycloalkyl, wherein: said C 1-4 -alkyl is optionally substituted with 1 to 3 substituents independently selected from fluoro, hydroxyl, C 1-3 -alkoxy, and fluoro-C 1-3 -alkoxy; and said C 3-6 -cycloalkyl is optionally substituted with 1 to 3 substituents independently selected from fluoro, hydroxyl, C 1-3 -alkyl, fluoro-C 1-3 -alkyl, C 1-3 -alkoxy, and fluoro-C 1-3 -alkoxy; R 2 is hydrogen, fluoro, CH 3 , -CH 2 F, -CHF 2 , or CF 3 ; R 3 is halogen, C 1-4 -alkyl, halo-C 1-4 -alkyl, C 1-4 -alkoxy, or halo-C 1-4 -alkoxy; R 4 is hydroxyl, C 1-6 -alkoxy, halo-C 1-6 -alkoxy, or -NR 5 R 6 ; R 5 is hydrogen, C 1-6 -alkyl, or halo-C 1-6 -alkyl; R 6 is hydrogen or C 1-6 -alkyl, wherein said C 1-6 -alkyl is optionally substituted with 1 to 6 substituents independently selected from halogen, -SO 3 H, and -CO 2 H; and n is 0 or 1; or a pharmaceutically acceptable salt, a stereoisomer, a mixture of stereoisomers, or a tautomer thereof. Q is phenylene or pyridylene, each of which is optionally substituted with one or two substituents selected from halogen, methyl, -CH 2 F, -CHF 2 , or -CF 3 ; Z is: L is selected from the group consisting of a bond, C 1-3 -alkylene, and C 1-3 -alkylene-O-; Y' is phenyl or pyridyl, wherein said phenyl and pyridyl are substituted with one, two, or three groups selected from halogen, C 1-3 -alkyl, fluoro-C 1-3 -alkyl, C 1-3 -alkoxy, and fluoro-C 1-3 -alkoxy; R 1 is C 1-4 -alkyl or C 3-6 -cycloalkyl, wherein: said C 1-4 -alkyl is optionally substituted with 1 to 3 substituents independently selected from fluoro, hydroxyl, C 1-3 -alkoxy, and fluoro-C 1-3 -alkoxy; and said C 3-6 -cycloalkyl is optionally substituted with 1 to 3 substituents independently selected from fluoro, hydroxyl, C 1-3 -alkyl, fluoro-C 1-3 -alkyl, C 1-3 -alkoxy, and fluoro-C 1-3 -alkoxy; said C 1-4 -alkyl is optionally substituted with 1 to 3 substituents independently selected from fluoro, hydroxyl, C 1-3 -alkoxy, and fluoro-C 1-3 -alkoxy; and said C 3-6 -cycloalkyl is optionally substituted with 1 to 3 substituents independently selected from fluoro, hydroxyl, C 1-3 -alkyl, fluoro-C 1-3 -alkyl, C 1-3 -alkoxy, and fluoro-C 1-3 -alkoxy; R 2 is hydrogen, fluoro, CH 3 , -CH 2 F, -CHF 2 , or CF 3 ; R 3 is halogen, C 1-4 -alkyl, halo-C 1-4 -alkyl, C 1-4 -alkoxy, or halo-C 1-4 -alkoxy; R 4 is hydroxyl, C 1-6 -alkoxy, halo-C 1-6 -alkoxy, or -NR 5 R 6 ; R 5 is hydrogen, C 1-6 -alkyl, or halo-C 1-6 -alkyl; R 6 is hydrogen or C 1-6 -alkyl, wherein said C 1-6 -alkyl is optionally substituted with 1 to 6 substituents independently selected from halogen, -SO 3 H, and -CO 2 H; and n is 0 or 1;